Research and Markets has announced the addition of the "Lewy body Dementia - Pipeline Review, H2 2016" report to their offering.
Lewy body Dementia Lewy Body Dementia (also called Dementia with Lewy bodies) is a form of dementia that shares characteristics with both Alzheimer's and Parkinson's diseases. Lewy bodies are abnormal microscopic protein deposits in the brain that disrupt the brain's normal functioning causing it to slowly deteriorate. Symptoms include visual hallucinations, movement disorders, cognitive problems and depression. Risk factors include age and family history. Treatment includes cholinesterase inhibitors, antipsychotic and Parkinson's disease medications.
Lewy body Dementia pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 2 and 1 respectively.
Lewy body Dementia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/w5q992/lewy_body
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005661/en/Business Wire
Last updated on: 28/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.